This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KA Kineta (KA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Kineta Stock (NASDAQ:KA) Get Kineta alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.57▼$0.8652-Week Range N/AVolume530,700 shsAverage Volume409,478 shsMarket Capitalization$7.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington. Read More Receive KA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kineta and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KA Stock News HeadlinesSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANTDecember 12, 2024 | prnewswire.comKineta and TuHURA Enter Acquisition AgreementNovember 25, 2024 | tipranks.comNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.October 10 at 2:00 AM | Brownstone Research (Ad)Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid TumorsOctober 18, 2024 | theglobeandmail.comKineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024October 4, 2024 | globenewswire.comKineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1October 2, 2024 | globenewswire.comKineta, Inc Transitioning from Nasdaq to OTC MarketsSeptember 19, 2024 | globenewswire.comKineta, Inc.: Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerAugust 19, 2024 | finanznachrichten.deSee More Headlines KA Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Kineta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kineta investors own include Intel (INTC), Motley Fool 100 Index ETF (TMFC), Argan (AGX), AST SpaceMobile (ASTS), AutoZone (AZO), Cadence Design Systems (CDNS) and Walt Disney (DIS). Company Calendar Today10/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KA CIK1445283 Webwww.kinetabio.com Phone(206) 378-0400FaxN/AEmployees40Year Founded2008Profitability EPS (Trailing Twelve Months)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.10 million Net MarginsN/A Pretax Margin-345.77% Return on Equity-1,044.95% Return on Assets-336.46% Debt Debt-to-Equity Ratio0.05 Current Ratio0.14 Quick Ratio0.14 Sales & Book Value Annual Sales$5.44 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / BookN/AMiscellaneous Outstanding Shares12,254,000Free Float9,350,000Market Cap$7.04 million OptionableNot Optionable Beta0.46 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:KA) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | SponsoredHave you heard of the Texas Royalty Plan?There is a backdoor way you could collect a check, four times a year, thanks to the exploding oil industry in ...Brownstone Research | SponsoredHow to Cash In on Trump’s Digital Current - Move By This ThursdayBitcoin Breakout: What Most Investors Are Missing Washington just approved more crypto legislation in 90 da...Investors Alley | SponsoredTesla’s $30 trillion pivotElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kineta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kineta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
